Apellis Pharmaceuticals, Inc.
APLS
Ранг среди акций
#3329
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Цена акции
$41.03
Последняя синхронизация: 2026-05-15
Рыночная капитализация
$5.25B
Изменение (1 день)
0.00%
Изменение (1 год)
51.57%
Страна
US
Торговля Apellis Pharmaceuticals, Inc. (APLS)
Категория
Healthcare
Коэффициент P/E для Apellis Pharmaceuticals, Inc. (APLS)
Коэффициент P/E на October 2026 TTM: 38.71
Согласно последним финансовым отчетам и цене акций Apellis Pharmaceuticals, Inc., текущий P/E (TTM) составляет 38.71. В конце 2023 у компании был P/E на уровне -13.44.
История P/E компании Apellis Pharmaceuticals, Inc. с 2013 по 2026
P/E на конец каждого года
| Год | P/E коэффициент | Изменить |
|---|---|---|
| 2026 (TTM) | 38.71 | -293.73% |
| 2024 | -19.98 | 48.68% |
| 2023 | -13.44 | 59.72% |
| 2022 | -8.41 | 57.33% |
| 2021 | -5.35 | -57.10% |
| 2020 | -12.47 | 102.70% |
| 2019 | -6.15 | 9.30% |
| 2018 | -5.63 | -61.35% |
| 2017 | -14.56 | 55.58% |
| 2016 | -9.36 | 71.49% |
| 2015 | -5.46 | -76.81% |
| 2014 | -23.53 | 44.99% |
| 2013 | -16.23 | 0.00% |
P/E для схожих компаний или конкурентов
| Компания | P/E Ratio | Разница P/E | Страна |
|---|---|---|---|
| 28.78 | -25.64% |
US
|
|
| -28.36 | -173.26% |
US
|
|
| -24.57 | -163.47% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | -21.64% |
NL
|
Как читать P/E Ratio?
Коэффициент цена/прибыль (P/E Ratio) отражает соотношение между ценой акции компании и её прибылью на акцию.
Низкий, но положительный P/E говорит о том, что компания приносит высокую прибыль при низкой оценке и может быть недооценена. Высокий отрицательный (близкий к 0) P/E указывает на значительные убытки.
Компании с P/E выше 30 или отрицательным считаются "акциями роста" — инвесторы ожидают роста или будущей прибыли.
Компании с положительным P/E ниже 10 считаются "ценностными акциями", т.е. уже прибыльны, но с низким потенциалом роста.